Format

Send to

Choose Destination
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):84-7.

Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma.

PMID:
27668050
PMCID:
PMC5013857

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center